The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model

The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model

Background: Dyskinesia or abnormal involuntary movements (AIMs) are a disabling effect of chronic l-DOPA administration and consequent pulsatile stimulation of dopamine receptors. This abnormal activation causes maladaptive changes including upregulation of FosB expression in dynorphin containing st...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Thornton, E, Hassall, M, Corrigan, F, Vink, R
Formato:	Journal article
Idioma:	English
Publicado em:	Elsevier 2014

Registros relacionados

Levodopa-Induced Dyskinesia Is Associated with Increased Thyrotropin Releasing Hormone in the Dorsal Striatum of Hemi-Parkinsonian Rats
por: Cantuti-Castelvetri, Ippolita, et al.
Publicado em: (2011)

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias
por: Rosario Sánchez-Pernaute, et al.
Publicado em: (2007-08-01)

Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
por: Masato Asanuma, et al.
Publicado em: (2013-01-01)

Parkinsonian patients and poor awareness of dyskinesias.
por: Sara ePietracupa, et al.
Publicado em: (2014-03-01)

Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
por: Abdallah Hadj Tahar, et al.
Publicado em: (2004-03-01)

Systematic Evaluation of DBS Parameters in the Hemi-Parkinsonian Rat Model
por: Soheil Mottaghi, et al.
Publicado em: (2020-10-01)

The beneficial effect of the flavonoid quercetin on behavioral changes in hemi-Parkinsonian rats
por: Mehdi Mehdizadeh, et al.
Publicado em: (2010-01-01)

The beneficial effect of the flavonoid quercetin on behavioral changes in hemi-Parkinsonian rats
por: Mehdi Mehdizadeh, et al.
Publicado em: (2010-01-01)

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
por: M. T. Herrero, et al.
Publicado em: (2023-05-01)

Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice
por: Ziqing Shi, et al.
Publicado em: (2020-11-01)

Synergistic Effects of Adenosine A2A Antagonist and L-DOPA on Rotational Behaviors in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Mouse Model
por: Takahiro Matsuya, et al.
Publicado em: (2007-01-01)

Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys
por: Marc Morissette, et al.
Publicado em: (2022-02-01)

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
por: Daniella Rylander, et al.
Publicado em: (2010-09-01)

IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
por: Romina Aron Badin, et al.
Publicado em: (2013-01-01)

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson′s disease
por: Emma Thornton, et al.
Publicado em: (2015-01-01)

CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
por: Boyce, S, et al.
Publicado em: (1990)

Potential efficacy of nanocurcumin on levodopa-induced dyskinesia in a rat parkinsonian model
por: Pegah Ashrafi, et al.
Publicado em: (2022-11-01)

Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates
Publicado em: (2013-01-01)

Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates.
por: Romina Aron Badin, et al.
Publicado em: (2013-01-01)

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets
por: Yutaro Ohno, et al.
Publicado em: (2023-07-01)

Advancing age and the rs6265 BDNF SNP are permissive to graft-induced dyskinesias in parkinsonian rats
por: Natosha M. Mercado, et al.
Publicado em: (2024-08-01)

Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup
por: Giuseppe Frazzitta, et al.
Publicado em: (2012-01-01)

Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats
por: Stefania eSgroi, et al.
Publicado em: (2014-10-01)

Chronic Nasal Administration of Kisspeptin-54 Regulates Mood-Related Disorders Via Amygdaloid GABA in Hemi-Parkinsonian Rats
por: Osman Sinen, et al.
Publicado em: (2024-11-01)

Molecular Insights into the Interaction of Tryptophan Metabolites with the Human Aryl Hydrocarbon Receptor in Silico: Tryptophan as Antagonist and no Direct Involvement of Kynurenine
por: Abdulla A-B Badawy, et al.
Publicado em: (2024-09-01)

NK1-r Antagonist Treatment Comparable to Decompressive Craniectomy in Reducing Intracranial Pressure Following Stroke
por: Annabel J. Sorby-Adams, et al.
Publicado em: (2019-07-01)

The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
por: Cristina Miguelez, et al.
Publicado em: (2011-01-01)

AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys
por: Mélanie Bourque, et al.
Publicado em: (2022-11-01)

Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline
por: G.C. Nascimento, et al.
Publicado em: (2023-03-01)

Dopaminergic-like neurons derived from oral mucosa stem cells by developmental cues improve symptoms in the hemi-parkinsonian rat model.
por: Javier Ganz, et al.
Publicado em: (2014-01-01)

The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation
por: Uros Velickovic, et al.
Publicado em: (2025-02-01)

ANTIEMETIC ACTIVITY OF NEUROKININ NK1 RECEPTOR ANTAGONISTS IS MEDIATED CENTRALLY IN THE FERRET
por: Gardner, C, et al.
Publicado em: (1994)

5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
por: Elisabetta Tronci, et al.
Publicado em: (2013-12-01)

Short and Long Term Behavioral and Pathological Changes in a Novel Rodent Model of Repetitive Mild Traumatic Brain Injury.
por: Kelly M McAteer, et al.
Publicado em: (2016-01-01)

Denervation and repeated l-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats
por: Michel St-Hilaire, et al.
Publicado em: (2003-10-01)

Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist–induced orofacial dyskinesia
por: Koki Nagaoka, et al.
Publicado em: (2021-05-01)

POS-431 ALTERED REGULATION OF TRYPTOPHAN METABOLISM AND ARYL HYDROCARBON RECEPTOR DISTRIBUTION IN RODENT POLYCYSTIC KIDNEYS
por: S. Nagao, et al.
Publicado em: (2021-04-01)

A sequential methodology for integral evaluation of motor and non-motor behaviors in parkinsonian rodents
por: Luis O. Soto-Rojas, et al.
Publicado em: (2020-01-01)

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
por: Giovanna Levandis, et al.
Publicado em: (2008-01-01)

Validation of a Precise Impactor in a Rodent Cervical Spinal Cord Injury Hemi-Contusion Model
por: Jose A. Castillo, et al.
Publicado em: (2024-11-01)